Home Synthesis and antioxidant activity of a series of novel 3-chalcone-substituted 1,4-dihydropyridine derivatives
Article Open Access

Synthesis and antioxidant activity of a series of novel 3-chalcone-substituted 1,4-dihydropyridine derivatives

  • Hao Sun , Chengxiang Shang , Longfei Jin and Jian Zhang EMAIL logo
Published/Copyright: December 8, 2012

Abstract

New 3-chalcone-substituted 1,4-dihydropyridine (DHP) derivatives have been synthesized based on dimethyl or diethyl 2,6-dimethyl-4-phenyl-1,4-DHP-3,5-dicarboxylate. Their structures were confirmed by IR, 1H NMR, 13C NMR, and elemental analyses. The synthesized compounds were also screened for antioxidant properties.

Introduction

1,4-Dihydropyridine (DHP) and its derivatives have been studied because of their biological activities (Fernandes et al., 2003; Matsubara et al., 2004; Ryabokon et al., 2005) such as antitubercular (Fassihi et al., 2009), anti-inflammatory (Klegeris et al., 2002), and antitumor properties (Abbsa et al., 2010). Some of these compounds have been used for the treatment of cardiovascular diseases (nifedipine and amlodipine). Their antioxidant properties (Diaz-Araya et al., 1998; Cominacini et al., 2003; Berkels et al., 2005; Borovic et al., 2006; Plotniece et al., 2009; Vijesh et al., 2011) have received more attention in recent years. Studies on cardiac and liver membranes point to an antioxidant protective effect of these compounds that may contribute to their pharmacological activity (Hassan et al., 2009).

Chalcone and its derivatives have been reported to possess various pharmacological activities, including anti-inflammatory, anticancer, and antioxidant properties (Anto et al., 1995; Liu et al., 2007). Both 1,4-DHP and chalcone have antioxidant properties. For a long time, we have been interested in the study of 1,4-DHPs bearing different substituents in the 3- and 5-positions. The structure-activity relationships of DHPs have indicated that the groups in the 3- and 5-positions are very important for pharmacological effects (Donkor et al., 1998; Foroumadi et al., 2002; Roh et al., 2008). It has been reported that DHPs substituted by flavone in the 4-position show a good bradycardic activity (Budriesi et al., 2005), but the DHPs substituted by flavone in the 3- or 5-position have not been described.

In view of these observations, we decided to introduce a chalcone moiety to the 3- or 5-position of the DHP ring, in the hope of changing the biological activities of these compounds. New 3-chalcone-substituted 1,4-DHP derivatives were synthesized, and their radical-scavenging effects investigated.

Results and discussion

Synthesis of compounds 4a–g

The synthetic route to compounds 4a–g is outlined in Schemes 13. The DHPs 1a,b (Scheme 1) were prepared using Hantzsch reaction (Hadizadeh et al., 2002). The monoester derivatives 2a,b were prepared by partial hydrolysis of 1a,b. The chalcones 3a–d (Schemes 2 and 3) were synthesized in high yields by using a general procedure reported in literature (Luo et al., 2012).

Scheme 1
Scheme 1
Scheme 2
Scheme 2
Scheme 3
Scheme 3

A subsequent condensation of 1,4-dihydropyridine acids (DHPAs) 2a,b with chalcones 3a–d furnished the desired 1,4-DHP derivatives 4a–g in 42–72% yields (Schemes 2 and 3).

Most of 1,4-DHP derivatives were prepared using a three-compound condensation reaction of β-keto ester, aromatic aldehyde, and ammonium hydroxide. At the beginning, we wanted to introduce the chalcone moiety directly to the 1,4-DHP ring by one-step synthesis. A chalcone containing a β-diketone group was allowed to react with aromatic aldehyde and ammonium hydroxide instead of β-keto ester. This approach was not successful. The target compounds 4a–g were synthesized via 4-dimethylamiopryidine (DMAP)/1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC•HCl)-catalyzed two-component condensation reaction of 1,4-DHP 2 and hydroxy-substituted chalcone. At first, we attempted to use dicyclohexylcarbodiimide (DCC) as a dehydrating agent, but the workup proved to be difficult. The preparation of 4a–g was successful with EDC•HCl as the dehydrating agent. The structures of these products were fully consistent with their IR, 1H NMR, and 13C NMR spectral data. The elemental analysis results were also satisfactory.

Antioxidant studies: DPPH radical-scavenging assay

This assay is based on the measurement of the scavenging ability of compounds toward the stable radical DPPH. Data for the decolorization of DPPH solution by the test samples are shown in Table 1, which express the free radical-scavenging capability. All compounds 4a–g exhibit free radical-scavenging activities. Thienyl derivatives 4c and 4f show better scavenging activities than the remaining compounds 4. Compared with compound 1a and 1b, compounds 4a–g showed downward trend of radical-scavenging activity.

Table 1

DPPH radical-scavenging activity of compounds 1a,b and 4a–g.

Compound4a4b4c4d4e
IC50m)313±24281±12172±8320±31254±12
4f4g1a1b
IC50m)184±10621±43132±7156±11

Conclusions

Compounds 4 are good scavengers of radicals.

Experimental section

IR spectra were taken in KBr pellets. 1H NMR and 13C NMR spectra were recorded in CDCl3 on a Bruker 400 spectrometer at 400 and 100 MHz, respectively.

General procedure for the synthesis of DHPs 1a,b

A solution of benzaldehyde (2.5 mL, 0.025 mol), a keto ester (4.4 mL, 0.05 mol), ammonium acetate (3.80 g, 0.05 mol), two drops of acetic acid, and two drops of piperidine in ethanol (50 mL) was stirred at the reflux temperature. After the completion of the reaction, as monitored by TLC, the solvent was removed under reduced pressure. The yellow residue of 1a,b was crystallized from ethanol.

Dimethyl 2,6-dimethyl-4-phenyl-1,4-DHP-3,5-dicarboxylate (1a)

Yellow crystals; yield 82%; mp 158–160°C; IR: 3340, 3060, 1712, 1690, 1650, 1631, 1370, 1123, 1090, 1020, 768, 703, 679 cm-1; 1H NMR: δ 7.14–7.42 (m, 5H), 5.70 (s, 1H), 4.92 (s, 1H), 3.57 (s, 6H), 2.32 (s, 6H).

Diethyl 2,6-dimethyl-4-phenyl-1,4-DHP-3,5-dicarboxylate (1b)

Yellow crystals; yield 84%; mp 159–160°C; IR: 3290, 2996, 1711, 1674, 1332, 1209, 1123, 1090, 1020, 767, 691, 679 cm-1; 1H NMR: δ 7.12–7.31 (m, 5H), 5.55 (s, 1H), 4.11 (m, 4H), 4.02 (s, 1H), 2.37 (s, 6H), 1.25 (t, 6H).

General procedure for the synthesis of compounds 2a,b

DHP 1a,b (0.01 mol) was suspended in methanol (30 mL) and treated with a solution of NaOH (1.60 g, 0.04 mol) in water at room temperature with stirring. The mixture was stirred under reflux for 5 h, cooled, quenched with water (200 mL), and filtered. The filtrate was treated with activated carbon (0.20 g), and the mixture was stirred at 55°C for 30 min. After cooling, the carbon was filtered off, the filtrate was acidified with 1 N HCl to pH 2.5, and the resultant precipitate of 2a,b was filtered and crystallized from methanol.

5-(Methoxycarbonyl)-2,6-dimethyl-4-phenyl-1,4-DHP-3-carboxylic acid (2a)

White crystals; yield 72%; mp 202–204°C; 1H NMR: δ 11.66 (s, 1H), 8.75 (s, 1H), 7.20–7.09 (m, 5H), 4.88 (s, 1H), 3.54 (s, 3H), 2.25 (s, 6H).

5-(Ethoxycarbonyl)-2,6-dimethyl-4-phenyl-1,4-DHP-3-carboxylic acid (2b)

White crystals; yield 75%; mp 191–192°C; 1H NMR: δ 11.64 (s, 1H), 8.72 (s, 1H), 7.20–7.10 (m, 5H), 4.88 (s, 1H), 3.99–3.55 (m, 2H), 2.26 (s, 6H), 1.19–1.15 (t, 3H).

General procedure for the synthesis of chalcones 3a–d

A mixture of a solution of KOH (5.60 g) in 40 mL methanol, 4-hydroxyacetophenone (0.02 mol), or 4-hydroxybenzaldehyde (0.02 mol) was stirred under nitrogen atmosphere for 24 h and then acidified with 1 N HCl to pH 1. The resultant yellow solid of 3a–d was filtered under reduced pressure and crystallized from methanol. The structures of compounds 3a–d were confirmed by comparison of their melting points with those reported in the literature; 3a: mp 181.2–182.3°C, lit. mp 180–182°C (Dimmock et al., 1998); 3b: mp 172.4–173.2°C, lit. mp 172–173°C (Dimmock et al., 1998); 3c: mp 172.6–173.8°C, lit. mp 172°C (Gul et al., 2008); 3d: mp 180.6–181.7°C, lit. mp 180–181°C (Dimmock et al., 1998).

General procedure for the synthesis of compounds 4a–g

A mixture of compound 2a,b (0.01 mol), compound 3a,d (0.01 mol), 4-dimethylaminopyridine (0.20 g), and a solution of EDC•HCl (1.00 g) in dichloromethane (50 mL) was stirred under a nitrogen atmosphere at room temperature for 24 h and then concentrated on a rotary evaporator (water bath at 38°C). The yellow residue of 4a–g was purified by silica gel column chromatography eluting with ethyl acetate/petroleum ether (1:4).

4-[3-(E)-(4-Methoxyphenyl)acryloyl]phenyl-5-methyl-2,6-dimethyl-4-phenyl-1,4-DHP-3,5-dicarboxylate (4a)

Yellow crystals; yield 72%; mp 101.1–102.3°C; IR: 3318, 3029, 2951, 1702, 1596 cm-1; 1H NMR: δ 8.02 (d, J = 8.2 Hz, 2H), 7.79 (d, J = 16.0 Hz, 1H), 7.61 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 16.0 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.30–7.27 (m, 3H), 7.08 (d, J = 8.0 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 5.90 (s, 1H), 5.19 (s, 1H), 3.88 (s, 3H), 3.68 (s, 3H), 1.28 (s, 6H); 13C NMR: δ 189.7, 168.1, 165.1, 161.8, 156.3, 154.7, 147.6, 145.0, 144.1, 135.5, 130.3, 129.9, 128.2, 127.9, 127.5, 126.5, 122.2, 119.6, 114.5, 104.7, 102.3, 55.4, 51.1, 39.7, 19.6, 19.2. Anal. Calcd for C32H29NO6: C, 73.41; H, 5.58; N, 2.68. Found: C, 73.27; H, 5.56; N, 2.64.

Methyl 4-[3-(E)-phenylacryloyl]phenyl-2,6-dimethyl-4-phenyl-1, 4-DHP-3,5-dicarboxylate (4b)

Yellow crystals; yield 62%; mp 92.3–94.1°C; IR: 3338, 3032, 2952, 1700, 1604 cm-1; 1H NMR: δ 8.03 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 16.0 Hz, 1H, -CH-), 7.66 (d, J = 6.6 Hz, 2H), 7.51 (d, J = 16.0 Hz, 1H), 7.45–7.44 (m, 3H), 7.37 (d, J = 8.8 Hz, 2H), 7.31–7.27 (m, 3H), 7.09 (d, J = 8.0 Hz, 2H), 5.68 (s, 1H), 5.19 (s, 1H), 3.68 (s, 3H), 2.43 (s, 3H), 2.41 (s, 3H); 13C NMR: δ 189.7, 168.0, 165.8, 156.4, 154.9, 147.5, 145.1, 143.9, 135.2, 134.8, 130.6, 130.0, 129.3, 129.0, 128.5, 128.2, 127.9, 122.3, 122.0, 104.8, 102.3, 51.1, 39.7, 19.7, 19.3. Anal. Calcd for C31H27NO5: C, 75.44; H, 5.51; N, 2.84. Found: C, 75.27; H, 5.44; N, 2.82.

Methyl 4-[3-(E)-(2-thienyl)acryloyl]phenyl-2,6-dimethyl-4-phenyl-1,4-DHP-3,5-dicarboxylate (4c)

Yellow crystals; yield 55%; mp 80.7–81.8°C; IR: 3336, 3026, 2946, 1698 cm-1; 1H NMR: δ 8.01 (d, J = 7.2 Hz, 2H), 7.55 (d, J = 15.6 Hz, 1H), 7.44 (br s, 1H), 7.37 (m, 3H), 7.31 (d, J = 15.6 Hz, 1H), 7.29 (d, J = 7.2 Hz, 2H), 7.21 (d, J = 6.8 Hz, 1H), 7.10 (m, 3H), 6.49 (s, 1H), 5.19 (s, 1H), 3.67 (s, 3H), 2.38, 2.36 (2s, 6H); 13C NMR: δ 190.0, 168.0, 165.7, 154.8, 147.5, 143.9, 140.2, 137.3, 135.1, 132.1, 130.0, 129.9, 129.0, 128.6, 128.4, 128.2, 127.9, 126.5, 122.3, 104.8, 102.4, 51.1, 39.7, 19.7, 19.3. Anal. Calcd for C29H25NO5S: C, 69.72; H, 5.04; N, 2.80; S, 6.42. Found: C, 69.58; H, 4.97; N, 2.75; S, 6.32.

Ethyl 4-[3-(E)-(4-methoxyphenyl)acryloyl]phenyl 2,6-dimethyl-4-phenyl-1,4-DHP-3,5-dicarboxylate (4d)

Yellow crystals; yield 68%; mp 98.8–100.4°C; IR: 3337, 3026, 2951, 1698, 1597 cm-1; 1H NMR: δ 8.02 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 16.0 Hz, 1H), 7.61 (d, 2H, J = 8.0 Hz, 2H), 7.39 (d, J = 16.0 Hz, 1H), 7.37–7.28 (m, 3H), 7.21 (d, J = 6.8 Hz, 2H), 7.076 (d, J = 8.0 Hz, 2H), 6.96 (d, J 6.8 Hz, 2H), 6.12 (s, 1H), 5.18 (s, 1H), 4.33–3.68 (m, 2H), 3.87 (s, 3H), 2.41 (s, 3H), 2.39 (s, 3H), 1.47–1.00 (m, 3H); 13C NMR: δ 189.7, 168.1, 165.9, 161.8, 156.4, 154.7, 147.6, 145.0, 144.2, 135.5, 130.4, 129.9, 128.2, 127.9, 127.5, 126.5, 122.2, 119.5, 114.5, 104.6, 102.2, 55.4, 51.1, 39.6, 19.7, 19.3, 14.3. Anal. Calcd for C33H31NO6: C, 73.73; H, 5.81; N, 2.61. Found: C, 73.58; H, 5.73; N, 2.56.

Ethyl 4-[3-(E)-phenylacryloylphenyl-1,4-dihydro-2,6-dimethyl-4-phenylpyridine-3,5-dicarboxylate (4e)

Yellow crystals; yield 67%; mp 87.2–88.5°C; IR: 3334, 3029, 2951, 1704, 1606 cm-1; 1H NMR: δ 8.05 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 15.6 Hz), 7.65 (d, J = 6.6 Hz, 2H), 7.54 (d, J = 15.6 Hz, 1H), 7.46–7.40 (m, 3H), 7.40 (d, J = 8.4 Hz), 7.32–7.26 (m, 3H), 7.11 (d, J = 8.0 Hz, 2H), δ 5.22, (s, 1H), δ 5.18 (s, 1H), δ 3.60–3.51 (m, 2H), δ 2.37 (s, 3H), 2.34 (s, 3H), δ 1.31–1.26 (m, 3H); 13C NMR: δ 189.7, 168.3, 166.0, 155.4, 155.0, 147.7, 145.2, 144.6, 135.2, 134.7, 130.8, 130.1, 129.1, 128.6, 128.4, 128.0, 126.6, 122.4, 121.9, 104.5, 101.9, 60.0, 39.7, 19.6, 19.1, 14.3. Anal. Calcd for C32H29NO5: C, 75.72; H, 5.76; N, 2.76. Found: C, 75.56; H, 5.69; N, 2.74.

Ethyl 4-[3-(E)-(2-thienyl)acryloylphenyl-1,4-dihydro-2,6-dimethyl-4-phenylpyridine-3,5-dicarboxylate (4f)

Yellow crystals; yield 42%; mp 78.2–79.6°C; IR: 3334, 3026, 2928, 1698, 1594 cm-1; 1H NMR: δ 8.01 (d, J = 8.8 Hz, 2H), 7.94 (d, J = 15.6 Hz, 1H), 7.38 (br s, 3H), 7.30 (d, J = 15.6, 1H), 7.28 (d, J = 8.8 Hz, 2H), 7.21 (br s, 2H), 7.11–7.07 (m, 3H), 5.97 (s, 1H), 5.18 (s, 1H), 3.68 (m, 2H), 2.42 (s, 3H), 2.40 (s, 1H), 1.28–1.23 (m, 3H); 13C NMR: δ 189.1, 168.3, 165.9, 155.0, 147.8, 144.6, 140.1, 137.3, 135.0, 132.4, 129.9, 129.3, 128.5, 128.2, 128.1, 127.9, 126.5, 122.4, 120.5, 104.4, 101.9, 60.0, 39.7, 19.5, 19.1, 14.32. Anal. Calcd for C30H27NO5S: C, 70.16; H, 5.30; N, 2.73: Found: C, 69.95; H, 5.27; N, 2.68.

Methyl 4-[3-oxo-3-phenylprop-1-(E)-enyl]phenyl-1,4-dihydro-2,6-dimethyl-4-phenylpyridine-3,5-dicarboxylate (4g)

Yellow crystals; yield 62%; mp 103.2–105.1°C; IR: 3339, 3026, 2948, 1698, 1603 cm-1; 1H NMR: δ 8.03 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 16.0 Hz, 1H), 7.65 (d, J = 6.8 Hz, 2H), 7.51 (d, J = 16.0 Hz, 1H), 7.44 (br s, 3H), 7.37 (d, J = 8.4 Hz, 2H), 7.31–7.19 (m, 3H), 7.09 (d, J = 7.2 Hz, 2H), 5.91 (s, 1H), 5.19 (s, 1H), 3.68 (s, 3H), 2.43 (s, 3H), δ 2.40 (s, 3H); 13C NMR: δ 189.7, 168.2, 165.9, 154.9, 148.1, 147.7, 145.2, 144.3, 135.2, 134.7, 130.8, 130.1, 129.1, 128.6, 128.2, 127.9, 126.5, 122.4, 121.9, 104.6, 102.1, 51.2, 39.7, 19.6, 19.2. Anal. Calcd for C31H27NO5: C, 75.44; H, 5.51; N, 2.84. Found: C, 74.34; H, 5.42; N, 2.80.

Evaluation of the antioxidative activity

The free radical-scavenging activity of test samples 4a–g was determined using DPPH. Briefly, a methanol solution (3 mL) of 100 μm DPPH was mixed with 1 mL of different concentrations (from 10-5 to 103 mol) of compound (1 mL), and the mixture was incubated at 40°C. A decrease in absorbance was measured at 517 nm (Hitachi 557 UV-VIS spectrophotometer). The inhibition of colorization was expressed as percentage and IC50 (obtained from the inhibition curve).


Corresponding author: Jian Zhang, College of Chemistry and Materials, South-Central University for Nationalities, Wuhan 430074, PR China

The authors express their thanks to the South-Central University for Nationalities for the financial support during this investigation.

References

Abbsa, H. S.; Sayed, W. A. E.; Fathy, N. M. Synthesis and antitumor activity of new dihydropyridine thioglycosides and their corresponding dehydrogenated forms. Eur. J. Med. Chem. 2010, 45, 973–982.Search in Google Scholar

Anto, R. J.; Sukumaran, K.; Kuttan, G.; Rao, M. N. A.; Subbaraju, V.; Kuttan, R. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett. 1995, 97, 33–37.Search in Google Scholar

Berkels, R.; Breitenbach, T.; Bartels, H.; Taubert, D.; Rosenkranz, A.; Klaus, W.; Roesen, R. Different antioxidative potencies of dihydropyridine calcium channel modulators in various models. Vasc. Pharmacol. 2005, 42, 145–152.Search in Google Scholar

Borovic, S.; Tirzitis, G.; Tirzite, D.; Cipak, A.; Khoschsorur, G. A.; Waeg, G.; Tatzber, F.; Scukanec-Spoljar, M.; Zarkovic, N. Bioactive 1,4-dihydroisonicotinic derivatives prevent oxidative damage of liver cells. Eur. J. Pharmacol. 2006, 537, 12–19.Search in Google Scholar

Budriesi, R.; Bisi, A.; Ioan, P.; Rampa, A.; Gobbi, S.; Belluti, F.; Piazzi, L.; Valenti, P.; Chiarini, P. 1,4-Dihydropyridine derivatives as calcium channel modulators: the role of 3-methoxy-flavone moiety. Bioorg. Med. Chem. 2005, 13, 3423–3430.Search in Google Scholar

Cominacini, L.; Pasini, A. F.; Garbin, U.; Pastorino, A. M.; Davoli, A.; Nava, C.; Campagnola, M.; Rossato, P.; Cascio, V. L. Antioxidant activity of different dihydropyridines. Biochem. Biophys. Res. Commun. 2003, 302, 679–684.Search in Google Scholar

Diaz-Araya, G.; Godoy, L.; Naranjo, L.; Squella, J. A.; Letelier, M. E.; Nunez-Vergara, L. J. Antioxidant effects of 1,4-dihydropyridine and nitroso aryl derivatives on the Fe3+/ascorbate-stimulated lipid peroxidation in rat brain slices. Gen. Pharmacol. Vasc. Syst. 1998, 31, 385–391.Search in Google Scholar

Dimmock, J. R.; Kandepu, N. M.; Hetherington, M. Quail, J. W.; Pugazhenthi, U.; Sudom, A. M.; Chamankhah, M.; Rose, P.; Pass, E.; Allen, T. M.; et al. Cytotoxic activities of Mannich bases of chalcones and related compounds. J. Med. Chem. 1998, 41, 1014–1026.Search in Google Scholar

Donkor, I. O.; Zhou, X. X.; Schmidt, J.; Agrawal, K. C.; Kishore, V. Synthesis and radioprotective effects of adamantyl substituted 1,4-dihydropyridine derivatives. Bioorg Med. Chem. 1998, 6, 563–568.Search in Google Scholar

Hadizadeh, F.; Shafiee, A.; Kazemi, R.; Mohammadi, M. Synthesis of 4-(1-phenylmethyl-5-imidazolyl)-1,4-dihydropyridines as calcium channel antagonists. Indian J. Chem. 2002, 41B, 2679–2682.Search in Google Scholar

Fassihi, A.; Azadpour, Z.; Delbari, N.; Saghaie, L.; Menarian, H. R.; Sabet, R.; Alborzi, A.; Miri, R.; Pourabbas, B.; Mardaneh, J.; et al. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3, 5-dicarboxamides. Eur. J. Med. Chem. 2009, 44, 3253–3258.Search in Google Scholar

Fernandes, M. A. S.; Santos, M. S.; Vicente, J. A. F.; Moreno, A. J. M.; Velena, A.; Duburs, G.; Oliveira, C. R. Effects of 1,4-dihydropyridine derivatives (cerebrocrast, gammapyrone, and diethone) on mitochondrial bioenergetics and oxidative stress: a comparative study. Mitochondrion 2003, 3, 47–59.Search in Google Scholar

Foroumadi, A.; Analuie, N.; Rezvanipour, M.; Sepehir, G.; Najafipour, H.; Javanmardi, K.; Esmaeeli, F. Synthesis and calcium channel antagonist activity of nifedipine analogues with methylthioimidazole substituent. Farmaco 2002, 57, 195–199.Search in Google Scholar

Gul, H. I.; Yerdelen, K. O.; Das, U.; Gul, M.; Pandit, B.; Li, P. K.; Dimmock, J. R. Synthesis and Cytotoxicity of novel 3-aryl-1-(3-dibenzylaminomethyl-4-hydroxyphenyl)-propenones and related compounds. Chem. Pharm. Bull. 2008, 56, 1675–1681.Search in Google Scholar

Hassan, H. A.; Abdel-Aziz, M.; Abuo-Rahma, G. E. A. A.; Farag, H. H. 1-Malonyl-1,4-dihydropyridine as a novel carrier for specific delivery of drugs to the brain. Bioorg. Med. Chem. 2009, 17, 1681–1692.Search in Google Scholar

Klegeris, A.; Liutkevicius, E.; Mikalauskiene, G.; Duburs, G.; McGeer, P. L.; Klusa, V. Anti-inflammatory effects of cerebrocrast in a model of rat paw edema and on mononuclear THP-1 cell. Eur. J. Pharmacol. 2002, 441, 203–208.Search in Google Scholar

Liu, Y. C.; Hsieh, C. W.; Wu, C. C.; Wung, B. S. Chalcone inhibits the activation of NF-κB and STAT3 in endothelial cells via endogenous electrophile. Life Sci. 2007, 80, 1420–1430.Search in Google Scholar

Luo, Y.; Song, R.; Li, Y.; Zhang, S.; Liu, Z. J. Design, synthesis, and biological evaluation of chalcone oxime derivatives as potential immunosuppressive agents. Bioorg. Med. Chem. Lett. 2012, 22, 3039–3043.Search in Google Scholar

Matsubara, M.; Hasegawa, K. Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur. J. Pharmacol. 2004, 498, 303–314.Search in Google Scholar

Plotniece, A.; Pajuste, K.; Kaldre, D.; Cekavicus, B.; Vigante, B.; Turovska, B.; Belyakov, S.; Sobolev, A.; Duburs, G. Oxidation of cationic 1,4-dihydropyridine derivatives as model compounds for putative gene delivery agents. Tetrahedron 2009, 65, 8344–8349.Search in Google Scholar

Roh, E. J.; Keller, J. M.; Olah, Z.; Iadarola, M. J.; Jacobson, K. A. Structure-activity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1). Bioorg. Med. Chem. 2008, 16, 9349–9358.Search in Google Scholar

Ryabokon, N. I.; Rzeszowska-Wolny, J.; Goncharova, R. I.; Duburs, G. A 1,4-dihydropiridine derivatives reduce DNA damage and stimulates DNA repair in human cells in vitro. Mutat. Res. 2005, 587, 52–58.Search in Google Scholar

Vijesh, A. M.; Isloor, A. M.; Peethambar, S. K.; Shivananda, K. N.; Arulmoli, T.; Isloor, N. A. Hantzsch reaction: synthesis and characterization of some new 1,4-dihydropyridine derivatives as potent antimicrobial and antioxidant agents. Eur. J. Med. Chem. 2011, 46, 5591–5597.Search in Google Scholar

Received: 2012-5-15
Accepted: 2012-10-10
Published Online: 2012-12-08
Published in Print: 2012-12-01

©2012 by Walter de Gruyter Berlin Boston

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded on 11.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hc-2012-0070/html
Scroll to top button